Table 2.

An overview of clinical trials investigating the effect of colchicine on acute coronary syndrome (ACS) or myocardial infarction (MI).

Author	Year	Country	Study design	Sex	Participants' disease	Colchicine dosage	Control	Age, years (intervention/control)	Duration of colchicine usage	Duration of follow-up	Sample size, N (intervention/control)	Endpoint (s)
Mariama Akodad [32]	2016	France	Clinical trial	Both	STEMI	Colchicine 1 mg daily+optimal medical care	Optimal medical care alone	60.1/59.7	1 month	1 month	23/21	CRP, all-cause mortality, GI adverse events
Thomas Hennessy [33]	2019	Australia	RCT	Both	Acute MI	0.5 mg daily	Placebo	61/61	1 month	1 month	119/118	hs-CRP, all-cause mortality, MI, GI adverse events
Nina C. Raju [34]	2011	Australia	RCT	Both	ACS or ischemic stroke	1 mg daily	Placebo	57.2/57.2	1 month	1 month	36/38	Hs-CRP, all-cause mortality, stroke, MI, GI adverse events
Spyridon Deftereos [35]	2015	Greece	RCT	Both	STEMI	Loading dose of 2 mg continuing with 0.5 mg bid (if body weight < 60 kg then 0.5 mg daily)	Placebo	58/58	5 days	5 days	77/74	hs-CRP, GI adverse events
Jean-Claude Tardif [36]	2019	Multinational	RCT	Both	MI	0.5 mg daily	Placebo	62.1/61.2	19.6 and 19.5 months in colchicine and placebo groups, respectively (median)	Median of 22.6 months overall and 6 months in hs-CRP substudy	2366/2379 overall and 99/108 in hs-CRP substudy	All-cause mortality, stroke, MI, GI adverse events
Trisulo Wasyanto [12]	2018	Indonesia	RCT	Both	Acute MI	0.5 mg daily	Placebo	57.8/52.8	5 days	5 days	16/16	hs-CRP
David C. Tong [19]	2020	Australia	RCT	Both	ACS	0.5 mg colchicine bid for the first month, followed by 0.5 mg daily for eleven months	Placebo	59.7/60.0	12 months	365 days	396/399	All-cause mortality, stroke, MI, GI adverse events

RCT: randomized controlled trial; ACS: acute coronary syndrome; MI: myocardial infarction; STEMI: ST-Elevation Myocardial Infarction; hs-CRP: high-sensitivity C-reactive protein; GI: gastrointestinal.